Back to top
more

Abeona Therapeutics (ABEO)

(Delayed Data from NSDQ)

$3.19 USD

3.19
1,103,021

+0.02 (0.63%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $3.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Philips (PHG) Showcases New AI-Based Solutions at the RSNA

by Zacks Equity Research

Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.

Philips (PHG) to Showcase New Innovations & Cardiac Solutions

by Zacks Equity Research

Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.

Philips (PHG) Expands Partnership to Build Angio CT Solution

by Zacks Equity Research

Philips (PHG) is building the world's first spectral detector angio CT solution by forging an alliance with the Leiden University Medical Center.

Philips (PHG) Alerts Users of Health Hazards of Therapy Masks

by Zacks Equity Research

Philips (PHG) cautions customers against health hazards faced by the users of CPAP or Bi-Level PAP therapy masks with magnetic headgear.

    Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

    by Zacks Equity Research

    Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

    Philips (PHG) Expands AI Portfolio With SmartSpeed Solution

    by Zacks Equity Research

    Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.

    Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

    by Zacks Equity Research

    Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

    F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

    by Zacks Equity Research

    Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

    Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

    by Zacks Equity Research

    Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

      ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

      by Zacks Equity Research

      ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

      Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

      by Zacks Equity Research

      Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

      FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy

      by Zacks Equity Research

      An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.

      FDA Committee Recommends bluebird's (BLUE) CALD Therapy

      by Zacks Equity Research

      An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.

      bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy

      by Zacks Equity Research

      Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.

      AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half

      by Zacks Equity Research

      Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.

      BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug

      by Zacks Equity Research

      BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.

      Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe

      by Zacks Equity Research

      Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.

      Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA

      by Zacks Equity Research

      Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.

      Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease

      by Zacks Equity Research

      Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.

      Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

      by Zacks Equity Research

      While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

      Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

      by Zacks Equity Research

      While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

      AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

      by Zacks Equity Research

      Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

      Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

      by Zacks Equity Research

      Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

      Philips' (PHG) Launches a Range of New Products at EuroPCR 2022

      by Zacks Equity Research

      Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.

      AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug

      by Zacks Equity Research

      AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene